{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T18:29:53Z","timestamp":1792348193207,"version":"4.4.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicon"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.toxicon.2018.10.006","type":"journal-article","created":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T13:18:29Z","timestamp":1539177509000},"page":"38-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["OnabotulinumtoxinA for adductor spasmodic dysphonia (ADSD): Functional results and the role of dosage"],"prefix":"10.1016","volume":"155","author":[{"given":"M.R.","family":"Marchese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"D'Alatri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.R.","family":"Bentivoglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Paludetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.toxicon.2018.10.006_bib1","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1136\/jnnp.63.5.688","article-title":"Female predominance in spasmodic dysphonia","volume":"63","author":"Adler","year":"1997","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"2","key":"10.1016\/j.toxicon.2018.10.006_bib2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1615\/CritRevImmunol.v30.i2.50","article-title":"Mode of action of botulinum neurotoxins: current vaccination strategies and molecular immune recognition","volume":"30","author":"Aoki","year":"2010","journal-title":"Crit. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.toxicon.2018.10.006_bib3","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1001\/archotol.127.4.389","article-title":"Impact on quality of life of botulinum toxin treatments for spasmodic dysphonia and oromandibular dystonia","volume":"127","author":"Bhattacharyya","year":"2001","journal-title":"Arch. Otolaryngol. Head Neck Surg."},{"issue":"1","key":"10.1016\/j.toxicon.2018.10.006_bib4","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.otohns.2008.10.033","article-title":"Dosage changes in patients with long-term botulinum toxin use for laryngeal dystonia","volume":"140","author":"Birkent","year":"2009","journal-title":"Otolaryngol. Head Neck Surg."},{"issue":"1","key":"10.1016\/j.toxicon.2018.10.006_bib5","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1468-1331.2010.03047.x","article-title":"Spasmodic dysphonia and botulinum toxin: experience from largest treatment series","volume":"17","author":"Blitzer","year":"2010","journal-title":"Eur. J. Neurol."},{"issue":"8","key":"10.1016\/j.toxicon.2018.10.006_bib6","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/lary.25273","article-title":"Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients","volume":"125","author":"Blitzer","year":"2015","journal-title":"Laryngoscope"},{"issue":"10","key":"10.1016\/j.toxicon.2018.10.006_bib7","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1097\/00005537-199810000-00003","article-title":"Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients","volume":"108","author":"Blitzer","year":"1998","journal-title":"Laryngoscope"},{"key":"10.1016\/j.toxicon.2018.10.006_bib8","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0021-9924(81)90037-X","article-title":"Spastic dysphonia: a continuum disorder","volume":"14","author":"Cannito","year":"1981","journal-title":"J. Comm. Dis."},{"issue":"1","key":"10.1016\/j.toxicon.2018.10.006_bib9","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2147\/CIA.S1416","article-title":"Vocal aging and adductor spasmodic dysphonia: response to botulinum toxin injection","volume":"3","author":"Cannito","year":"2008","journal-title":"Clin. Interv. Aging"},{"issue":"10","key":"10.1016\/j.toxicon.2018.10.006_bib10","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1002\/lary.22168","article-title":"Patient perceptions of factors leading to spasmodic dysphonia: a combined clinical experience of 350 patients","volume":"121","author":"Childs","year":"2011","journal-title":"Laryngoscope"},{"issue":"Suppl. 4","key":"10.1016\/j.toxicon.2018.10.006_bib11","doi-asserted-by":"crossref","first-page":"S168","DOI":"10.1002\/lary.22050","article-title":"Adductor spasmodic dysphonia changes in dosing after prolonged injections","volume":"121","author":"Chinosornvatana","year":"2011","journal-title":"Laryngoscope"},{"issue":"5","key":"10.1016\/j.toxicon.2018.10.006_bib12","first-page":"622","article-title":"Current practices in the management of adductor spasmodic dysphonia","volume":"39","author":"Eskander","year":"2010","journal-title":"J. Otolaryngol. Head Neck Surg."},{"issue":"5","key":"10.1016\/j.toxicon.2018.10.006_bib13","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.toxicon.2008.12.008","article-title":"Treatment of focal dystonias with botulinum neurotoxin","volume":"54","author":"Hallett","year":"2009","journal-title":"Toxicon"},{"issue":"12","key":"10.1016\/j.toxicon.2018.10.006_bib14","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1177\/000348940711601204","article-title":"Long-term botulinum toxin dose consistency for treatment of adductor spasmodic dysphonia","volume":"116","author":"Holden","year":"2007","journal-title":"Ann. Otol. Rhinol. Laryngol."},{"key":"10.1016\/j.toxicon.2018.10.006_bib15","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1044\/1058-0360.0603.66","article-title":"The voice handicap index (VHI)","volume":"6","author":"Jacobson","year":"1997","journal-title":"Am. J. Speech Lang. Pathol"},{"issue":"4","key":"10.1016\/j.toxicon.2018.10.006_bib16","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S0892-1997(98)80055-6","article-title":"The effect of patient factors on response outcomes to botox treatment of spasmodic dysphonia","volume":"12","author":"Lundy","year":"1998","journal-title":"J. Voice"},{"key":"10.1016\/j.toxicon.2018.10.006_bib17","article-title":"Central voice production and pathophysiology of spasmodic dysphonia","author":"Mor","year":"2017","journal-title":"Laryngoscope"},{"issue":"1","key":"10.1016\/j.toxicon.2018.10.006_bib18","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jvoice.2016.01.006","article-title":"Botulinum toxin dosing trends in spasmodic dysphonia over a 20-year period","volume":"31","author":"Namin","year":"2017","journal-title":"J. Voice"},{"issue":"13","key":"10.1016\/j.toxicon.2018.10.006_bib19","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1002\/mds.23254","article-title":"Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX\u00ae) across multiple indications","volume":"25","author":"Naumann","year":"2010","journal-title":"Mov. Disord."},{"issue":"3","key":"10.1016\/j.toxicon.2018.10.006_bib20","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/lary.21395","article-title":"Botulinum toxin treatment of adductor spasmodic dysphonia: longitudinal functional outcomes","volume":"121","author":"Novakovic","year":"2011","journal-title":"Laryngoscope"},{"issue":"3","key":"10.1016\/j.toxicon.2018.10.006_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvoice.2014.08.011","article-title":"Factors influencing botulinum toxin dose instability in spasmodic dysphonia patients","volume":"29","author":"Rosow","year":"2015","journal-title":"J. Voice"},{"issue":"2","key":"10.1016\/j.toxicon.2018.10.006_bib22","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/00005537-200202000-00004","article-title":"Risk factors and demographics in patients with spasmodic dysphonia","volume":"112","author":"Schweinfurth","year":"2002","journal-title":"Laryngoscope"},{"issue":"6","key":"10.1016\/j.toxicon.2018.10.006_bib23","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/01.moo.0000145959.50513.5e","article-title":"Contemporary management of spasmodic dysphonia","volume":"12","author":"Sulica","year":"2004","journal-title":"Curr. Opin. Otolaryngol. Head Neck Surg."},{"issue":"3","key":"10.1016\/j.toxicon.2018.10.006_bib24","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/lary.25551","article-title":"Onabotulinum toxin A dosage trends over time for adductor spasmodic dysphonia: a 15-year experience","volume":"126","author":"Tang","year":"2016","journal-title":"Laryngoscope"},{"issue":"7","key":"10.1016\/j.toxicon.2018.10.006_bib25","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1177\/000348941112000708","article-title":"Spasmodic dysphonia: onset, course, socioemotional effects and treatment response","volume":"120","author":"Tanner","year":"2011","journal-title":"Ann. Otol. Rhinol. Laryngol."},{"issue":"5","key":"10.1016\/j.toxicon.2018.10.006_bib26","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/lary.22471","article-title":"Case-control study of risk factors for spasmodic dysphonia: a comparison with other voice disorders","volume":"122","author":"Tanner","year":"2012","journal-title":"Laryngoscope"},{"key":"10.1016\/j.toxicon.2018.10.006_bib27","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1044\/vvd22.3.104","article-title":"Epidemiologic advances in spasmodic dysphonia","volume":"22","author":"Tanner","year":"2012","journal-title":"Perspect. Voice Voice Disord."},{"issue":"10","key":"10.1016\/j.toxicon.2018.10.006_bib28","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/lary.20564","article-title":"Influence of age and gender on dose effectiveness of botulinum toxin for laryngeal dystonia","volume":"119","author":"Vasconcelos","year":"2009","journal-title":"Laryngoscope"},{"issue":"1","key":"10.1016\/j.toxicon.2018.10.006_bib29","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jvoice.2004.03.006","article-title":"Voice handicap index results for older patients with adductor spasmodic dysphonia","volume":"191","author":"Wingate","year":"2005","journal-title":"J. Voice"},{"issue":"5","key":"10.1016\/j.toxicon.2018.10.006_bib30","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jvoice.2013.10.024","article-title":"Relationship of laryngeal botulinum toxin dosage to patient age, vitality and socioeconomic issues","volume":"28","author":"Young","year":"2014","journal-title":"J. Voice"}],"container-title":["Toxicon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041010118303994?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041010118303994?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,5]],"date-time":"2018-11-05T20:04:04Z","timestamp":1541448244000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041010118303994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":30,"alternative-id":["S0041010118303994"],"URL":"https:\/\/doi.org\/10.1016\/j.toxicon.2018.10.006","relation":{},"ISSN":["0041-0101"],"issn-type":[{"value":"0041-0101","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"OnabotulinumtoxinA for adductor spasmodic dysphonia (ADSD): Functional results and the role of dosage","name":"articletitle","label":"Article Title"},{"value":"Toxicon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.toxicon.2018.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}